-
1
-
-
0028609624
-
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
-
Weinstat-Saslow DL, Zabrenetzky VS, vanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-11.
-
(1994)
Cancer Res
, vol.54
, pp. 6504-6511
-
-
Weinstat-Saslow, D.L.1
Zabrenetzky, V.S.2
vanHoutte, K.3
Frazier, W.A.4
Roberts, D.D.5
Steeg, P.S.6
-
2
-
-
0001651169
-
Design and therapeutic application of matrix metalloproteinase inhibitors
-
Whittaker M, Floyd CD, Bowen P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99: 2735-76.
-
(1999)
Chem Rev
, vol.99
, pp. 2735-2776
-
-
Whittaker, M.1
Floyd, C.D.2
Bowen, P.3
Gearing, A.J.H.4
-
3
-
-
77950931419
-
Matrix metalloproteinases: Regulators of the tumor microenviroment
-
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenviroment. Cell 2010; 141: 52-67.
-
(2010)
Cell
, vol.141
, pp. 52-67
-
-
Kessenbrock, K.1
Plaks, V.2
Werb, Z.3
-
4
-
-
38049177345
-
Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis
-
Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007; 104: 20262-7.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 20262-20267
-
-
Ardi, V.C.1
Kupriyanova, T.A.2
Deryugina, E.I.3
Quigley, J.P.4
-
5
-
-
79955698736
-
Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: A review
-
Yadav RK, Gupta SP, Sharma PK, Patil VM. Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review. Curr Med Chem 2011; 18:1704-22.
-
(2011)
Curr Med Chem
, vol.18
, pp. 1704-1722
-
-
Yadav, R.K.1
Gupta, S.P.2
Sharma, P.K.3
Patil, V.M.4
-
6
-
-
34547398983
-
Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors
-
Gupta SP. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors. Chem Rev 2007; 107: 3042-87.
-
(2007)
Chem Rev
, vol.107
, pp. 3042-3087
-
-
Gupta, S.P.1
-
7
-
-
47349084576
-
Progress in the development of matrix metalloproteinase inhibitors
-
Tu G, Xu W, Huang H, Li S. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem 2008; 15: 1388-95.
-
(2008)
Curr Med Chem
, vol.15
, pp. 1388-1395
-
-
Tu, G.1
Xu, W.2
Huang, H.3
Li, S.4
-
8
-
-
20044388325
-
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer
-
Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005; 23: 842-9.
-
(2005)
J Clin Oncol
, vol.23
, pp. 842-849
-
-
Bissett, D.1
O'Byrne, K.J.2
von Pawel, J.3
-
9
-
-
0037975559
-
Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats
-
Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003; 48: 1742-9.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 1742-1749
-
-
Renkiewicz, R.1
Qiu, L.2
Lesch, C.3
-
10
-
-
0031716672
-
Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor
-
Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 1998; 80(5): 907-8.
-
(1998)
J Bone Joint Surg Br
, vol.80
, Issue.5
, pp. 907-908
-
-
Hutchinson, J.W.1
Tierney, G.M.2
Parsons, S.L.3
Davis, T.R.4
-
11
-
-
77955652686
-
Biaryl substituted hydantoin compounds as TACE inhibitors
-
Yu W, Tong L, Kim SH, et al. Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett. 2010; 20(17): 5286-9.
-
(2010)
Bioorg Med Chem Lett.
, vol.20
, Issue.17
, pp. 5286-5289
-
-
Yu, W.1
Tong, L.2
Kim, S.H.3
-
12
-
-
0037112183
-
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer
-
Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434-9.
-
(2002)
J Clin Oncol
, vol.20
, Issue.22
, pp. 4434-4439
-
-
Shepherd, F.A.1
Giaccone, G.2
Seymour, L.3
-
13
-
-
14044274265
-
Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies
-
Rao BG. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 2005; 11(3): 295-322.
-
(2005)
Curr Pharm Des
, vol.11
, Issue.3
, pp. 295-322
-
-
Rao, B.G.1
-
14
-
-
4444341426
-
The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories
-
Wada CK. The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr Top Med Chem 2004; 4(12): 1255-67.
-
(2004)
Curr Top Med Chem
, vol.4
, Issue.12
, pp. 1255-1267
-
-
Wada, C.K.1
-
15
-
-
33745963397
-
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study
-
Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 2006; 102(2): 300-8.
-
(2006)
Gynecol Oncol
, vol.102
, Issue.2
, pp. 300-308
-
-
Hirte, H.1
Vergote, I.B.2
Jeffrey, J.R.3
-
16
-
-
0043238937
-
Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model
-
Nozaki S, Sissons S, Chien DS, Sledge GW Jr. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. Clin Exp Metastasis 2003; 20(5): 407-12.
-
(2003)
Clin Exp Metastasis
, vol.20
, Issue.5
, pp. 407-412
-
-
Nozaki, S.1
Sissons, S.2
Chien, D.S.3
Sledge Jr., G.W.4
-
17
-
-
23644441594
-
Identification of potent and selective MMP-13 inhibitors
-
Wu J, Rush TS III, Hotchandani R, et al. Identification of potent and selective MMP-13 inhibitors. Bioorg Med Chem Lett 2005; 15(18): 4105-9.
-
(2005)
Bioorg Med Chem Lett
, vol.15
, Issue.18
, pp. 4105-4109
-
-
Wu, J.1
Rush III, T.S.2
Hotchandani, R.3
-
18
-
-
0034635966
-
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
-
Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000; 97(8): 4052-7.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, Issue.8
, pp. 4052-4057
-
-
Zhou, Z.1
Apte, S.S.2
Soininen, R.3
-
19
-
-
80052032038
-
Inflammation in osteoarthritis
-
Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011; 23(5): 471-8.
-
(2011)
Curr Opin Rheumatol
, vol.23
, Issue.5
, pp. 471-478
-
-
Goldring, M.B.1
Otero, M.2
-
21
-
-
0029666453
-
Understanding the P1' specificity of the matrix metalloproteinases: Effect of S1' pocket mutations in matrilysin and stromelysin-1
-
Welch AR, Holman CM, Huber M, Brenner MC, Browner MF, Van Wart HE. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. Biochemistry 1996; 35(31): 10103-9.
-
(1996)
Biochemistry
, vol.35
, Issue.31
, pp. 10103-10109
-
-
Welch, A.R.1
Holman, C.M.2
Huber, M.3
Brenner, M.C.4
Browner, M.F.5
Van Wart, H.E.6
-
22
-
-
0029030448
-
Matrilysin-inhibitor complexes: Common themes among metalloproteases
-
Browner MF, Smith WW, Castelhano AL. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995; 34(20): 6602-10.
-
(1995)
Biochemistry
, vol.34
, Issue.20
, pp. 6602-6610
-
-
Browner, M.F.1
Smith, W.W.2
Castelhano, A.L.3
-
23
-
-
0033048045
-
Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors
-
Lovejoy B, Welch AR, Carr S, et al. Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 1999; 6(3): 217-21.
-
(1999)
Nat Struct Biol
, vol.6
, Issue.3
, pp. 217-221
-
-
Lovejoy, B.1
Welch, A.R.2
Carr, S.3
-
24
-
-
34447617899
-
Structure-based design of TACE selective inhibitors: Manipulations in the S1'-S3' pocket
-
Huang A, Joseph-McCarthy D, Lovering F, et al. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. Bioorg Med Chem 2007; 15(18): 6170-81.
-
(2007)
Bioorg Med Chem
, vol.15
, Issue.18
, pp. 6170-6181
-
-
Huang, A.1
Joseph-McCarthy, D.2
Lovering, F.3
-
25
-
-
33646053826
-
Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453
-
Kohno T, Hochigai H, Yamashita E, Tsukihara T, Kanaoka M. Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453. Biochem Biophys Res Commun 2006; 344(1): 315-22.
-
(2006)
Biochem Biophys Res Commun
, vol.344
, Issue.1
, pp. 315-322
-
-
Kohno, T.1
Hochigai, H.2
Yamashita, E.3
Tsukihara, T.4
Kanaoka, M.5
-
26
-
-
77954219616
-
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alphasulfone hydroxamates
-
Kolodziej SA, Hockerman SL, Boehm TL, et al. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alphasulfone hydroxamates. Bioorg Med Chem Lett 2010; 20(12): 3557-60.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, Issue.12
, pp. 3557-3560
-
-
Kolodziej, S.A.1
Hockerman, S.L.2
Boehm, T.L.3
-
27
-
-
77956763130
-
Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease
-
Becker DP, Barta TE, Bedell LJ, et al. Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. J Med Chem 2010; 53(18): 6653-80.
-
(2010)
J Med Chem
, vol.53
, Issue.18
, pp. 6653-6680
-
-
Becker, D.P.1
Barta, T.E.2
Bedell, L.J.3
-
28
-
-
68549135187
-
N-O-isopropyl sulfonamido-based hydroxamates: Design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis
-
Nuti E, Casalini F, Avramova SI, et al. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J Med Chem 2009; 52(15): 4757-73.
-
(2009)
J Med Chem
, vol.52
, Issue.15
, pp. 4757-4773
-
-
Nuti, E.1
Casalini, F.2
Avramova, S.I.3
-
29
-
-
0035935193
-
Alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1
-
Becker DP, Barta TE, Bedell L, et al. Alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1. Bioorg Med Chem Lett 2001; 11(20): 2719-22.
-
(2001)
Bioorg Med Chem Lett
, vol.11
, Issue.20
, pp. 2719-2722
-
-
Becker, D.P.1
Barta, T.E.2
Bedell, L.3
-
30
-
-
39749124201
-
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
-
Li JJ, Nahra J, Johnson AR, et al. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J Med Chem 2008; 51(4): 835-41.
-
(2008)
J Med Chem
, vol.51
, Issue.4
, pp. 835-841
-
-
Li, J.J.1
Nahra, J.2
Johnson, A.R.3
-
31
-
-
67651123042
-
3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding
-
Li W, Hu Y, Li J, et al. 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding. Bioorg Med Chem Lett 2009; 19(16): 4546-50.
-
(2009)
Bioorg Med Chem Lett
, vol.19
, Issue.16
, pp. 4546-4550
-
-
Li, W.1
Hu, Y.2
Li, J.3
-
32
-
-
66749184678
-
Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13
-
Monovich LG, Tommasi RA, Fujimoto RA, et al. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. J Med Chem 2009; 52(11): 3523-38.
-
(2009)
J Med Chem
, vol.52
, Issue.11
, pp. 3523-3538
-
-
Monovich, L.G.1
Tommasi, R.A.2
Fujimoto, R.A.3
-
33
-
-
34948864524
-
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects
-
Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007; 282(38): 27781-91.
-
(2007)
J Biol Chem
, vol.282
, Issue.38
, pp. 27781-27791
-
-
Johnson, A.R.1
Pavlovsky, A.G.2
Ortwine, D.F.3
-
34
-
-
67650045889
-
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models
-
Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009; 60(7): 2008-18.
-
(2009)
Arthritis Rheum
, vol.60
, Issue.7
, pp. 2008-2018
-
-
Baragi, V.M.1
Becher, G.2
Bendele, A.M.3
-
35
-
-
77955661111
-
SAR studies of non-zincchelating MMP-13 inhibitors: Improving selectivity and metabolic stability
-
Gao DA, Xiong Z, Heim-Riether A, et al. SAR studies of non-zincchelating MMP-13 inhibitors: improving selectivity and metabolic stability. Bioorg Med Chem Lett 2010; 20(17): 5039-43.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, Issue.17
, pp. 5039-5043
-
-
Gao, D.A.1
Xiong, Z.2
Heim-Riether, A.3
-
36
-
-
68949125078
-
Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors
-
Heim-Riether A, Taylor SJ, Liang S, et al. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. Bioorg Med Chem Lett 2009; 19(18): 5321-4.
-
(2009)
Bioorg Med Chem Lett
, vol.19
, Issue.18
, pp. 5321-5324
-
-
Heim-Riether, A.1
Taylor, S.J.2
Liang, S.3
-
37
-
-
80255136352
-
Identification of novel, exositebinding matrix metalloproteinase-13 inhibitor scaffolds
-
Roth J, Minond D, Darout E, et al. Identification of novel, exositebinding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett 2011; 21(23): 7180-4.
-
(2011)
Bioorg Med Chem Lett
, vol.21
, Issue.23
, pp. 7180-7184
-
-
Roth, J.1
Minond, D.2
Darout, E.3
-
38
-
-
20144369218
-
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14
-
Blagg JA, Noe MC, Wolf-Gouveia LA, et al. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 2005; 15(7): 1807-10.
-
(2005)
Bioorg Med Chem Lett
, vol.15
, Issue.7
, pp. 1807-1810
-
-
Blagg, J.A.1
Noe, M.C.2
Wolf-Gouveia, L.A.3
-
39
-
-
84856400550
-
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis
-
Cege C, Bao B, Bluhm H, et al. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J Med Chem 2012; 55 (2): 709-16.
-
(2012)
J Med Chem
, vol.55
, Issue.2
, pp. 709-716
-
-
Cege, C.1
Bao, B.2
Bluhm, H.3
-
40
-
-
82555187389
-
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13
-
Taylor SJ, Abeywardane A, Liang S, et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem 2011; 54(23): 8174-87.
-
(2011)
J Med Chem
, vol.54
, Issue.23
, pp. 8174-8187
-
-
Taylor, S.J.1
Abeywardane, A.2
Liang, S.3
-
41
-
-
84055221868
-
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases
-
Marques SM, Tuccinardi T, Nuti E, et al. Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases J Med Chem 2011; 54 (24): 8289-98.
-
(2011)
J Med Chem
, vol.54
, Issue.24
, pp. 8289-8298
-
-
Marques, S.M.1
Tuccinardi, T.2
Nuti, E.3
-
42
-
-
78650424066
-
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
-
Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278(1): 16-27.
-
(2011)
FEBS J
, vol.278
, Issue.1
, pp. 16-27
-
-
Gialeli, C.1
Theocharis, A.D.2
Karamanos, N.K.3
-
43
-
-
10744223801
-
Physiological levels of tumstatin, a fragment of collagen IV 3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via V3 integrin
-
Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV 3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via V3 integrin. Cancer Cell 2003; 3: 589-601.
-
(2003)
Cancer Cell
, vol.3
, pp. 589-601
-
-
Hamano, Y.1
Zeisberg, M.2
Sugimoto, H.3
-
44
-
-
0000391746
-
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
-
Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
-
(2000)
Nat Cell Biol
, vol.2
, pp. 737-744
-
-
Bergers, G.1
Brekken, R.2
McMahon, G.3
-
45
-
-
38049177345
-
Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis
-
Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007; 104: 20262-67.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 20262-20267
-
-
Ardi, V.C.1
Kupriyanova, T.A.2
Deryugina, E.I.3
Quigley, J.P.4
-
46
-
-
0029829166
-
Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells
-
Festuccia C, Bologna M, Vicentini C, et al. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996; 69(5): 386-93.
-
(1996)
Int J Cancer
, vol.69
, Issue.5
, pp. 386-393
-
-
Festuccia, C.1
Bologna, M.2
Vicentini, C.3
-
47
-
-
58149348622
-
Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression
-
Castellano G, Malaponte G, Mazzarino MC, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008; 14(22): 7470-80.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.22
, pp. 7470-7480
-
-
Castellano, G.1
Malaponte, G.2
Mazzarino, M.C.3
-
48
-
-
1042290312
-
A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node positive breast carcinoma
-
Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node positive breast carcinoma. Clin Cancer Res 2004; 10: 1057-63.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 1057-1063
-
-
Leppa, S.1
Saarto, T.2
Vehmanen, L.3
Blomqvist, C.4
Elomaa, I.5
-
49
-
-
79958782153
-
Role of serum matrix metalloproteinase-2 and-9 to predict breast cancer progression
-
Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and-9 to predict breast cancer progression. Clin Biochem 2011; 44(10-11): 869-72.
-
(2011)
Clin Biochem
, vol.44
, Issue.10-11
, pp. 869-872
-
-
Patel, S.1
Sumitra, G.2
Koner, B.C.3
Saxena, A.4
-
50
-
-
0032031861
-
Reduced angiogenesis and tumor progression in gelatinase Adeficient mice
-
Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase Adeficient mice. Cancer Res 1998; 58(5): 1048-51.
-
(1998)
Cancer Res
, vol.58
, Issue.5
, pp. 1048-1051
-
-
Itoh, T.1
Tanioka, M.2
Yoshida, H.3
Yoshioka, T.4
Nishimoto, H.5
Itohara, S.6
-
51
-
-
0034628453
-
Design and synthesis of piperazinebased matrix metalloproteinase inhibitors
-
Cheng M, De B, Pikul S, et al. Design and synthesis of piperazinebased matrix metalloproteinase inhibitors. J Med Chem 2000; 43(3): 369-80.
-
(2000)
J Med Chem
, vol.43
, Issue.3
, pp. 369-380
-
-
Cheng, M.1
De, B.2
Pikul, S.3
-
52
-
-
16944365890
-
Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR
-
Hajduk PJ, Sheppard G, Nettesheim DG, et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc 1997; 119(25): 5818-27.
-
(1997)
J Am Chem Soc
, vol.119
, Issue.25
, pp. 5818-5827
-
-
Hajduk, P.J.1
Sheppard, G.2
Nettesheim, D.G.3
-
53
-
-
0037011911
-
Phenoxyphenyl sulfone Nformylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors
-
Wada CK, Holms JH, Curtin ML, et al. Phenoxyphenyl sulfone Nformylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J Med Chem 2002; 45(1): 219-32.
-
(2002)
J Med Chem
, vol.45
, Issue.1
, pp. 219-232
-
-
Wada, C.K.1
Holms, J.H.2
Curtin, M.L.3
-
54
-
-
33750689843
-
Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity
-
Qu X, Yuan Y, Xu W, et al. Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity. Anticancer Res 2006; 26(5A): 3573-8.
-
(2006)
Anticancer Res
, vol.26
, Issue.5 A
, pp. 3573-3578
-
-
Qu, X.1
Yuan, Y.2
Xu, W.3
-
55
-
-
43749091066
-
Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors
-
Cheng XC, Wang Q, Fang H, Tang W, Xu WF. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Bioorg Med Chem 2008; 16(10): 5398-404.
-
(2008)
Bioorg Med Chem
, vol.16
, Issue.10
, pp. 5398-5404
-
-
Cheng, X.C.1
Wang, Q.2
Fang, H.3
Tang, W.4
Xu, W.F.5
-
56
-
-
84863270811
-
Design of barbituratenitrate hybrids that inhibit MMP-9 activity and secretion
-
Just Accepted Manuscript, DOI: 10.1021/jm201352k
-
Wang J, S'Sullivan S, Harmon S, et al. Design of barbituratenitrate hybrids that inhibit MMP-9 activity and secretion. J Med Chem 2012; Just Accepted Manuscript, DOI: 10.1021/jm201352k
-
(2012)
J Med Chem
-
-
Wang, J.1
S'Sullivan, S.2
Harmon, S.3
-
57
-
-
79961173981
-
N-substituted homopiperazine barbiturates as gelatinase inhibitors
-
Wang J, Medina C, Radomski MW, Gilmer JF. N-substituted homopiperazine barbiturates as gelatinase inhibitors. Bioorg Med Chem 2011; 19(16): 4985-99.
-
(2011)
Bioorg Med Chem
, vol.19
, Issue.16
, pp. 4985-4999
-
-
Wang, J.1
Medina, C.2
Radomski, M.W.3
Gilmer, J.F.4
-
58
-
-
51849144056
-
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity
-
Ledour G, Moroy G, Rouffet M, et al. Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. Bioorg Med Chem 2008; 16(18): 8745-59.
-
(2008)
Bioorg Med Chem
, vol.16
, Issue.18
, pp. 8745-8759
-
-
Ledour, G.1
Moroy, G.2
Rouffet, M.3
-
59
-
-
62749157590
-
Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors
-
Rubino MT, Agamennone M, Campestre C, et al. Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors. ChemMedChem 2009; 4(3): 352-62.
-
(2009)
ChemMedChem
, vol.4
, Issue.3
, pp. 352-362
-
-
Rubino, M.T.1
Agamennone, M.2
Campestre, C.3
-
60
-
-
22144461050
-
Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A
-
Ikejiri M, Bernardo MM, Meroueh SO, et al. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 2005; 70(14): 5709-12.
-
(2005)
J Org Chem
, vol.70
, Issue.14
, pp. 5709-5712
-
-
Ikejiri, M.1
Bernardo, M.M.2
Meroueh, S.O.3
-
61
-
-
79951531008
-
Sulfonate-containing thiiranes as selective gelatinase inhibitors
-
Testero SA, Lee M, Staran RT, et al. Sulfonate-containing thiiranes as selective gelatinase inhibitors. ACS Med Chem Lett 2011; 2: 177-81.
-
(2011)
ACS Med Chem Lett
, vol.2
, pp. 177-181
-
-
Testero, S.A.1
Lee, M.2
Staran, R.T.3
-
62
-
-
79955150446
-
Exploring the functional space of thiiranes as gelatinase inhibitors using click chemistry
-
Testero SA, Llarrull LI, Fisher JF, Chang M, Mobashery S. Exploring the functional space of thiiranes as gelatinase inhibitors using click chemistry. ARKIVOC 2011; 7: 221-36.
-
(2011)
ARKIVOC
, vol.7
, pp. 221-236
-
-
Testero, S.A.1
Llarrull, L.I.2
Fisher, J.F.3
Chang, M.4
Mobashery, S.5
-
63
-
-
0034686685
-
Potent and selective mechanism-based inhibition of gelatinases
-
Brown S, Bernardo M, Li ZH, et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000; 122: 6799-800.
-
(2000)
J Am Chem Soc
, vol.122
, pp. 6799-6800
-
-
Brown, S.1
Bernardo, M.2
Li, Z.H.3
-
64
-
-
79961234156
-
Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities
-
Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J Med Chem 2011; 54(15): 5532-9.
-
(2011)
J Med Chem
, vol.54
, Issue.15
, pp. 5532-5539
-
-
Zhang, Y.1
Fang, H.2
Feng, J.3
Jia, Y.4
Wang, X.5
Xu, W.6
-
65
-
-
58149086406
-
Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: Iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates
-
Marques SM, Nuti E, Rossello A, et al. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J Med Chem 2008; 51(24): 7968-79.
-
(2008)
J Med Chem
, vol.51
, Issue.24
, pp. 7968-7979
-
-
Marques, S.M.1
Nuti, E.2
Rossello, A.3
-
66
-
-
39749190017
-
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes
-
Zhu Z, Mazzola R, Sinning L, et al. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes. J Med Chem 2008; 51(4): 725-36.
-
(2008)
J Med Chem
, vol.51
, Issue.4
, pp. 725-736
-
-
Zhu, Z.1
Mazzola, R.2
Sinning, L.3
-
67
-
-
34548670257
-
Crystal structures of MMP-9 complexes with five inhibitors: Contribution of the flexible Arg424 side-chain to selectivity
-
Tochowicz A. Maskos K, Huber R, et al. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol 2007; 371: 989-1006.
-
(2007)
J Mol Biol
, vol.371
, pp. 989-1006
-
-
Tochowicz, A.1
Maskos, K.2
Huber, R.3
-
68
-
-
2542448200
-
Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2
-
Zhang W, Hou TJ, Qiao XB, Huai S, Xu XJ. Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2. J Mol Model 2004; 10: 112-20.
-
(2004)
J Mol Model
, vol.10
, pp. 112-120
-
-
Zhang, W.1
Hou, T.J.2
Qiao, X.B.3
Huai, S.4
Xu, X.J.5
-
69
-
-
23644438889
-
A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors
-
Gupta SP, Kumaran S. A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors. Bioorg Med Chem 2005; 13: 5454-62.
-
(2005)
Bioorg Med Chem
, vol.13
, pp. 5454-5462
-
-
Gupta, S.P.1
Kumaran, S.2
-
70
-
-
0037401628
-
Quantitative structure-activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines
-
Gupta SP, Kumar D, Kumaran SA. Quantitative structure-activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. Bioorg Med Chem 2003; 11: 1975-81.
-
(2003)
Bioorg Med Chem
, vol.11
, pp. 1975-1981
-
-
Gupta, S.P.1
Kumar, D.2
Kumaran, S.A.3
-
71
-
-
49149123555
-
Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors
-
Tuccinardi T, Nuti E, Ortore G, Rossello A, Avramova SI, Martinelli A. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors. Bioorg Med Chem 2008; 16(16): 7749-58.
-
(2008)
Bioorg Med Chem
, vol.16
, Issue.16
, pp. 7749-7758
-
-
Tuccinardi, T.1
Nuti, E.2
Ortore, G.3
Rossello, A.4
Avramova, S.I.5
Martinelli, A.6
-
72
-
-
68149149512
-
Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors
-
Tuccinardi T, Ortore G, Santos MA, et al. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors. J Chem Inf Model 2009; 49(7): 1715-24.
-
(2009)
J Chem Inf Model
, vol.49
, Issue.7
, pp. 1715-1724
-
-
Tuccinardi, T.1
Ortore, G.2
Santos, M.A.3
-
73
-
-
77149131528
-
To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition
-
Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 2010; 1803(1): 72-94.
-
(2010)
Biochim Biophys Acta
, vol.1803
, Issue.1
, pp. 72-94
-
-
Jacobsen, J.A.1
Major Jourden, J.L.2
Miller, M.T.3
Cohen, S.M.4
-
74
-
-
18444397733
-
Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor
-
Roswell S, Hawtin P, Minshull CA, et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 2002; 319: 173-81.
-
(2002)
J Mol Biol
, vol.319
, pp. 173-181
-
-
Roswell, S.1
Hawtin, P.2
Minshull, C.A.3
-
76
-
-
79959230769
-
The impact of ionization states of matrix metalloproteinase inhibitors on docking-based inhibitor design
-
Zhong H, Wees MA, Faure TD, Carrillo C, Arbiser J, Bowen JP. The impact of ionization states of matrix metalloproteinase inhibitors on docking-based inhibitor design. ACS Med Chem Lett 2011; 2: 455-460.
-
(2011)
ACS Med Chem Lett
, vol.2
, pp. 455-460
-
-
Zhong, H.1
Wees, M.A.2
Faure, T.D.3
Carrillo, C.4
Arbiser, J.5
Bowen, J.P.6
-
77
-
-
34248596450
-
Computational protocol for predicting the binding affinities of zinc containing metalloprotein-ligand complexes
-
Jain T, Jayaram B. Computational protocol for predicting the binding affinities of zinc containing metalloprotein-ligand complexes. Proteins: Struct Funct Bioinfo 2007; 67: 1167-78.
-
(2007)
Proteins: Struct Funct Bioinfo
, vol.67
, pp. 1167-1178
-
-
Jain, T.1
Jayaram, B.2
-
78
-
-
50249107450
-
Peptide hydrolysis catalyzed by matrix metalloprotein 2: A computational study
-
Díaz N, Suárez D. Peptide hydrolysis catalyzed by matrix metalloprotein 2: A computational study. J Phys Chem B 2008; 112: 8412-24.
-
(2008)
J Phys Chem B
, vol.112
, pp. 8412-8424
-
-
Díaz, N.1
Suárez, D.2
-
79
-
-
78149451538
-
QM/MM studies of the matrix metalloproteinase 2 (MMP2) inhibition mechanism of (S)-SB-3CT and its oxirane analogue
-
Zhou J, Tao P, Fisher JF, Shi Q, Mobashery S, Schlegel HB. QM/MM studies of the matrix metalloproteinase 2 (MMP2) inhibition mechanism of (S)-SB-3CT and its oxirane analogue. J Chem Theory Comput 2010; 6: 3580-7.
-
(2010)
J Chem Theory Comput
, vol.6
, pp. 3580-3587
-
-
Zhou, J.1
Tao, P.2
Fisher, J.F.3
Shi, Q.4
Mobashery, S.5
Schlegel, H.B.6
-
80
-
-
79957706173
-
Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression
-
Dejonckheere E, Vandenbroucke RE, Libert C. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev 2011; 22(2): 73-81.
-
(2011)
Cytokine Growth Factor Rev
, vol.22
, Issue.2
, pp. 73-81
-
-
Dejonckheere, E.1
Vandenbroucke, R.E.2
Libert, C.3
-
81
-
-
67349212939
-
Matrix metalloproteinase 12 silencing: A therapeutic approach to treat pathological lung tissue remodeling?
-
Garbacki N, Di Valentin E, Piette J, Cataldo D, Crahay C, Colige A. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm Pharmacol Ther 2009; 22(4): 267-78.
-
(2009)
Pulm Pharmacol Ther
, vol.22
, Issue.4
, pp. 267-278
-
-
Garbacki, N.1
Di Valentin, E.2
Piette, J.3
Cataldo, D.4
Crahay, C.5
Colige, A.6
-
82
-
-
79957651592
-
Matrix metalloproteinases: Protective roles in cancer
-
Decock J, Thirkettle S, Wagstaff L, Edwards DR. Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med 2011; 15(6): 1254-65.
-
(2011)
J Cell Mol Med
, vol.15
, Issue.6
, pp. 1254-1265
-
-
Decock, J.1
Thirkettle, S.2
Wagstaff, L.3
Edwards, D.R.4
|